Frontiers in Pharmacology (Apr 2018)
Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Abstract
No abstracts available.Keywords
Frontiers in Pharmacology (Apr 2018)